ACADIA PharmaceuticalsMEX:ACAD 73 Net Debt Paydown Yield % is 0.01% as of Jul. 06, 2026, which is 67% below its 10-year median of 0.03. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN495.48 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 1,159 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 51.94% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, ACADIA Pharmaceuticals's Net Debt Paydown Yield % was 0.01%.
ACADIA Pharmaceuticals (MEX:ACAD) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
ACADIA Pharmaceuticals Net Debt Paydown Yield % Related Terms
ACADIA Pharmaceuticals Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Net Debt Paydown Yield % Chart
MEX:ACAD vs VKTX, EWTX, DNLI: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.01% mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Net Debt Paydown Yield % of 0.01% as of Jul. 06, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ACADIA Pharmaceuticals and its competitors. This is 67% below median its historical median of 0.03. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #602 out of 1159 companies in the Biotechnology industry, placing it in the top 51.9%.
Is ACADIA Pharmaceuticals' Net Debt Paydown Yield % too high?
ACADIA Pharmaceuticals' current Net Debt Paydown Yield % of 0.01% is 67% below median its 10-year median of 0.03. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. ACADIA Pharmaceuticals' value of 0.01% is 66.7% below this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #602 out of 1159 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Net Debt Paydown Yield % compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #602 out of 1159 companies for Net Debt Paydown Yield %. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. ACADIA Pharmaceuticals' value of 0.01% is 66.7% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.03, ACADIA Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Net Debt Paydown Yield % of 0.01% is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Net Debt Paydown Yield % is 0.01%, which is 67% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN495.48, compared to a current price of MXN362.00 — trading 26.9% below its estimated fair value. The current Net Debt Paydown Yield % is 0.01%, which is 67% below median its 10-year median of 0.03 and 66.7% below the Biotechnology industry median of 0.03. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Net Debt Paydown Yield % is 0.01% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN362.00 is trading 26.9% below its estimated GF Value™ of MXN495.48.
GuruFocus considers ACADIA Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:ACAD:
Net Debt Paydown Yield %: 0.01% (67% below median its 10-year median of 0.03)
GF Value™: MXN495.48 vs. price of MXN362.00 (26.9% below fair value)
Industry Position: 66.7% below the Biotechnology median (#602 of 1159)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
